Targeting Peptides

Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma.

CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier.

CXCL8 (54-72) is a C-terminal peptide based on the chemokine CXCL8. CXCL8 (54-72) has an interaction between a long and highly positively charged C-terminal region and a negative charge on the GAG that binds to the GAG. CXCL8 (54-72) can inhibit the adhesion and migration of neutrophils and adhesion of endothelial cells. CXCL8 (54-72) can be used to study chemokines in inflammatory response.

G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology

NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging.

Cyclo(RADfK) can be used as a control for Cyclo(-RGDfK) (HY-P0023).

Heart-homing peptide TFA is a Pentapeptide, CRPPR. CRPPR is a linear peptide containing arginine that has been identified as a heart-homing peptide owing to its ability to specifically bind to heart endothelium, and cysteine-rich protein-2 (CRIP-2) has been proposed as the receptor. Heart-homing peptide TFA can be used for conjugating liposomes.

LyP-1 is a cyclic 9-amino-acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells.

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia.

DBCO-cyclo (RGDfK) is a clickable DBCO-modified cyclic RGD peptide, and also a DBCO derivative of cyclo (RGDfK) (HY-P0023). DBCO-cyclo (RGDfK) is synthesized via an amide coupling reaction between DBCO-NHS ester and cyclo (RGDfK). DBCO-cyclo (RGDfK) can react with azide groups through copper-free click chemistry (SPAAC) to immobilize RGD peptides onto biomaterials or hydrogels. The RGD sequence in DBCO-cyclo (RGDfK) is recognizable by cellular integrins and promotes cell adhesion. DBCO-cyclo (RGDfK) can be used in studies related to tissue engineering, 3D cell culture, and surface functionalization of biomaterials.

Kidney-targeting peptide is a kidney-targeting peptide (KTP). Kidney-targeting peptide significantly enhances the renal targeting ability of Isoquercitrin (HY-N1445). Kidney-targeting peptide can be used in diabetic nephropathy research.

tLyP-1 peptide is an NRP-1 targeting peptide with an IC₅₀ of 4 μM, and its amino acid sequence is CGNKRTR. tLyP-1 peptide specifically binds to NRP-1 to target tumor cells.

3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research.

CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects.

Skeletal muscle-targeted peptide MSP is a 7-amino-acid (ASSLNIA) muscle-targeting peptide (MTP). Skeletal muscle-targeted peptide MSP can target the virus through a different binding ligand to the muscle. Skeletal muscle-targeted peptide MSP can be used for the research of diseases of the heart and skeletal muscles.

cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging.

CGGRGD TFA, a RGD derivative with cysteine as its N-terminal.

FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand.

mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206.

DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation.